Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.

You may also be interested in...



GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal

Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.

GSK Drawn To Archemix’s Table By Aptamers For (Another) Option Deal

Package of seven potential anti-inflammatory drugs includes interleukin-23 inhibitor program.

Deals Of The Week: GSK/Dynavax, Wyeth Thiakis, Pfizer/Auxilium ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel